<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099060</url>
  </required_header>
  <id_info>
    <org_study_id>I170</org_study_id>
    <secondary_id>CAN-NCIC-IND170</secondary_id>
    <secondary_id>CDR0000389155</secondary_id>
    <nct_id>NCT00099060</nct_id>
  </id_info>
  <brief_title>Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>A Phase I/II Study of GW572016 in Patients With Recurrent Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of lapatinib and to&#xD;
      see how well it works in treating patients with recurrent glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Phase I&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of lapatinib in&#xD;
           patients with recurrent malignant glioblastoma multiforme who are taking CYP3A4&#xD;
           enzyme-inducing anti-epileptic drugs (EIAEDs).&#xD;
&#xD;
        -  Determine the toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      Phase II&#xD;
&#xD;
        -  Determine the efficacy of this drug, in terms of objective tumor response rate, in&#xD;
           patients who are taking EIAEDs and in those who are not taking EIAEDs.&#xD;
&#xD;
        -  Correlate immunohistochemical measures of cellular proteins and receptors from tumor&#xD;
           samples with anti-tumor activity of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label, phase I, dose-escalation study followed by a&#xD;
      phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive oral lapatinib twice daily on days 1-28. Courses repeat every&#xD;
           28 days in the absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of lapatinib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive lapatinib as in phase I at the MTD. Patients are followed at&#xD;
           1 month and then periodically for survival. Patients with stable or responding disease&#xD;
           who go off therapy are followed every 3 months for up to one year and then periodically&#xD;
           thereafter for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for the phase I portion of this&#xD;
      study within 18 months. A total of 15-30 patients will be accrued for the phase II portion of&#xD;
      this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity for phase I assessed by CTCAE v.3.0 MacDonald criteria</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response for phase II</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlative studies on archival tissue</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <description>For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):&#xD;
Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).&#xD;
Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.&#xD;
For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):&#xD;
• Phase II: 750 mg GW572016 po b.i.d.&#xD;
For all patients:&#xD;
• Dose reductions as required based on adverse events.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant glioblastoma multiforme&#xD;
&#xD;
          -  Recurrent or progressive disease after prior primary treatment with radiotherapy with&#xD;
             or without adjuvant chemotherapy&#xD;
&#xD;
          -  Bidimensionally measurable disease on CT scan or MRI with at least one lesion ≥ 1 cm x&#xD;
             1 cm&#xD;
&#xD;
          -  Paraffin embedded tumor sample available&#xD;
&#xD;
          -  Concurrent enzyme-inducing anti-epileptic drugs (EIAEDs) required for phase I of the&#xD;
             study&#xD;
&#xD;
               -  Patients in phase II of the study may or may not be receiving EIAEDs&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 50% by echocardiogram or MUGA&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No active cardiomyopathy&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary disease requiring oxygen&#xD;
&#xD;
        Neurologic&#xD;
&#xD;
          -  No preexisting peripheral neuropathy ≥ grade 3&#xD;
&#xD;
          -  No history of significant neurologic disorder that would preclude study compliance or&#xD;
             ability to give informed consent&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No upper gastrointestinal or other conditions that would preclude compliance with oral&#xD;
             medication&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, curatively treated carcinoma in situ of the cervix, or&#xD;
             other curatively treated solid tumor&#xD;
&#xD;
          -  No immune deficiency&#xD;
&#xD;
          -  No history of significant psychiatric disorder (e.g., uncontrolled psychotic&#xD;
             disorders) that would preclude study compliance or ability to give informed consent&#xD;
&#xD;
          -  No other serious illness or medical condition that would preclude study participation&#xD;
&#xD;
          -  No known hypersensitivity to compounds of similar chemical or biological composition&#xD;
             to lapatinib&#xD;
&#xD;
          -  No active uncontrolled or serious infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF), sargramostim (GM-CSF), or other&#xD;
             hematopoietic growth factors&#xD;
&#xD;
               -  Concurrent hematopoietic growth factors allowed for treatment of acute toxicity&#xD;
                  (e.g., febrile neutropenia)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy for recurrent disease&#xD;
&#xD;
          -  No more than one prior chemotherapy regimen in the adjuvant setting&#xD;
&#xD;
               -  At least 6 months since prior adjuvant chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent steroids allowed provided the dose is stable for at least 14 days before&#xD;
             study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  H2 blockers and proton pump inhibitors allowed, unless they are CYP3A4 inducers or&#xD;
             inhibitors&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent administration of any of the following&#xD;
             CYP3A4 inhibitors:&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Troleandomycin&#xD;
&#xD;
               -  Telithromycin&#xD;
&#xD;
               -  Ciprofloxacin&#xD;
&#xD;
               -  Norfloxacin&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Voriconazole&#xD;
&#xD;
               -  Fluconazole (≤150 mg/day allowed)&#xD;
&#xD;
               -  Nefazodone&#xD;
&#xD;
               -  Fluovoxamine&#xD;
&#xD;
               -  Delavirdine&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
               -  Amprenavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Saquinavir&#xD;
&#xD;
               -  Lopinavir&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Aprepitant&#xD;
&#xD;
               -  Grapefruit or grapefruit juice&#xD;
&#xD;
               -  Bitter orange&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent administration of any of the following&#xD;
             CYP3A4 inducers:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Rifapentine&#xD;
&#xD;
               -  Efavirenz&#xD;
&#xD;
               -  Nevirapine&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Modafinil&#xD;
&#xD;
          -  At least 6 months since prior and no concurrent administration of amiodarone&#xD;
&#xD;
          -  Antacids (e.g., mylanta, maalox, tums, rennies) must be administered ≥ 1 hour before&#xD;
             and ≥ 1 hour after study drug&#xD;
&#xD;
          -  At least 2 days since prior and no concurrent cimetidine&#xD;
&#xD;
          -  No other concurrent anti-cancer agents&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian A. Thiessen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L-4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>December 8, 2004</study_first_submitted>
  <study_first_submitted_qc>December 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2004</study_first_posted>
  <last_update_submitted>January 24, 2014</last_update_submitted>
  <last_update_submitted_qc>January 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

